Factor XIII (fibrin stabilising factor) in Henoch-Schönlein's purpura.
In 13 out of 17 consecutive children with Henoch-Schönlein's purpura the factor XIII determined with the dansyl cadaverine method was found to be decreased during the acute phase. The decrease is assumed to be due to a specific degradation by proteolytic enzymes liberated from inflammatory cells, with defective local haemostasis as a result. This assumption is strengthened by the observation that treatment with factor XIII combined with an antifibrinolytic drug controlled life-threatening gastro-intestinal bleeding in one of the patients. It would therefore appear that such treatment might offer a new possibility of controlling severe haemorrhages in Henoch-Schönlein's purpura.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005176:Factor XIII / Q000032:analysis / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006801:Humans; D011695:IgA Vasculitis / Q000097:blood* / Q000175:diagnosis; D008297:Male; D010958:Plasminogen / Q000032:analysis
D005340:Fibrinogen; D010958:Plasminogen; D005176:Factor XIII